Filtering

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 146 ()

DOP020

Prediction of clinical and endoscopic remission after autologous stem cell transplantation in treatment refractory Crohns disease: pooled results from the ASTIC trial

Year: 2016
Authors:

J. Lindsay*1, M. Allez2, M. Clark3, M. Labopin4, E. Ricart5, G. Rogler6, M. Rovira7, J. Satsangi8, D. Farge9, C. Hawkey3

1Blizard Institute, Barts and the London School of Medicine, Centre for Immunobiology, London, United Kingdom, 2APHP St. Antoine Hospital, Department of Gastroenterology, Paris, France, 3Nottingham Digestive Diseases Centre, Department of Digestive Diseases, Biomedical Research Unit, Nottingham, United Kingdom, 4European Group for Blood and Marrow Transplantation (EBMT), Paris, France, 5Hospital Clinic Barcelona, Gastroenterology, Barcelona, Spain, 6University Hospital Zürich, Department of Gastroenterology and Hepatology, Zürich, Switzerland, 7Hospital Clinic de Barcelona, Department of Haematology, Barcelona, Spain, 8Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom, 9Hospital Saint-Louis, Department of Internal Medicine and Vascular Pathology, Inserm U 976, Paris, France

1University Hospitals Leuven, Dpt of Gastroenterology, Leuven, Belgium 2Mayo Clinic College of Medicine, Gastroenterology and Hepatology, Rochester, United States 3Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States 4Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials, London, Canada 5University of California - San Diego, Division of Gastroenterology, La Jolla, United States 6Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States 7Humanitas University, Italy, Gastrointestinal Immunopathology, Milan, Italy 8Academic Medical Centre, Dept. of Gastroenterology, Amsterdam, Netherlands 9University of Cambridge, Division of Gastroenterology and Hepatology, Cambridge, United Kingdom 10University of Calgary, Department of Medicine, Calgary, Canada 11University of Chicago Medicine Inflammatory Bowel Disease Center, Section of Gastroenterology, Hepatology, and Nutrition, Chicago, United States 12Shafran Gastroenterology Research center, Gastroenterology, Winter Park, United States 13Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland 14Takeda Development Centre Europe Ltd, Global Statistics and Statistical Programming, London, United Kingdom 15Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom 16Takeda Development Centre Europe Ltd, Clinical Development, London, United Kingdom

DOP021

Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study

Year: 2017
Source:

1University Hospitals Leuven, Dpt of Gastroenterology, Leuven, Belgium 2Mayo Clinic College of Medicine, Gastroenterology and Hepatology, Rochester, United States 3Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States 4Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials, London, Canada 5University of California - San Diego, Division of Gastroenterology, La Jolla, United States 6Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States 7Humanitas University, Italy, Gastrointestinal Immunopathology, Milan, Italy 8Academic Medical Centre, Dept. of Gastroenterology, Amsterdam, Netherlands 9University of Cambridge, Division of Gastroenterology and Hepatology, Cambridge, United Kingdom 10University of Calgary, Department of Medicine, Calgary, Canada 11University of Chicago Medicine Inflammatory Bowel Disease Center, Section of Gastroenterology, Hepatology, and Nutrition, Chicago, United States 12Shafran Gastroenterology Research center, Gastroenterology, Winter Park, United States 13Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland 14Takeda Development Centre Europe Ltd, Global Statistics and Statistical Programming, London, United Kingdom 15Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom 16Takeda Development Centre Europe Ltd, Clinical Development, London, United Kingdom

Authors:

Vermeire S.*1, Loftus E.V.2, Colombel J.-F.3, Feagan B.4, Sandborn W.5, Sands B.6, Danese S.7, D'Haens G.8, Kaser A.9, Panaccione R.10, Rubin D.11, Shafran I.12, O'Byrne S.13, Geransar P.13, Previtali A.14, Khalid J.M.15, Kaviya A.16

DOP021

Long-term efficacy of autologous haematopoietic stem cells transplantation for refractory Crohns disease: 10 years of Milan experience without CD34+ cell selection

Year: 2016
Authors:

A. Cassinotti*1, F. Onida2, C. Annaloro2, G. Saporiti2, M. Fichera1, M. Daperno3, B. Motta2, P. Fociani4, E. Tagliaferri2, G. Sampietro5, D. Vincenti2, A. Gregorini2, G. Maconi1, M. Nebuloni6, A. Cortelezzi2, S. Ardizzone1

1Gastroenterology Unit, Luigi Sacco University Hospital, Milan, Italy, 2Bone Marrow Transplantation Centre, Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy, 3Gastroenterology Unit, AO Ordine Mauriziano, Turin, Italy, 4Luigi Sacco University Hospital, Pathology Unit, Milan, Italy, 52nd Division of Surgery, Luigi Sacco University Hospital, Milan, Italy, 6Pathology Unit, Luigi Sacco University Hospital, Milan, Italy

DOP022

Targeting immune cell metabolism: LYC-30937, a novel therapeutic approach for inflammatory bowel disease

Year: 2016
Authors:

L. Carter1, R. Morgan1, C. Lesch1, M. Spahr1, L. Franchi2, I. Monteleone3, G. Monteleone3, G. Glick2, H. J. Wilkins1, P. Higgins*2

1Lycera, Ann Arbor, Michigan, United States, 2University of Michigan, Ann Arbor, Michigan, United States, 3Tor Vergata, Rome, Italy

1Gastroenterology Outpatient Clinic, Heidelberg, Germany 2Gastroenterologist in Private Practice, Berlin, Germany 3Evidera, Montreal, Canada 4Evidera, Hammersmith, United Kingdom 5UBC: An Express Scripts Company, Montreal, Canada 6Takeda Pharma GmbH, Berlin, Germany 7Takeda Pharmaceuticals International AG, Zurich, Switzerland 8Takeda Development Centre Europe Ltd, London, United Kingdom

DOP022

Vedolizumab and anti-TNFα treatment effectiveness in patients with IBD treated in Germany: a retrospective chart review

Year: 2017
Source:

1Gastroenterology Outpatient Clinic, Heidelberg, Germany 2Gastroenterologist in Private Practice, Berlin, Germany 3Evidera, Montreal, Canada 4Evidera, Hammersmith, United Kingdom 5UBC: An Express Scripts Company, Montreal, Canada 6Takeda Pharma GmbH, Berlin, Germany 7Takeda Pharmaceuticals International AG, Zurich, Switzerland 8Takeda Development Centre Europe Ltd, London, United Kingdom

Authors:

Ehehalt R.*1, Schubert S.2, Stein D.3, Lambrelli D.4, Bassel M.5, Orzechowski H.-D.6, Minda K.7, Khalid J.M.8

1University of California - San Diego, La Jolla, United States 2Indiana University School of Medicine, Indianapolis, United States 3Mayo Clinic, Rochester, United States 4Dartmouth-Hitchcock Medical Center, Lebanon, United States 5Cleveland Clinic Foundation, Cleveland, United States 6Icahn School of Medicine at Mount Sinai, New York, United States 7Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States 8North Shore University Hospital, Manhasset, United States 9Lenox Hill Hospital, New York, United States 10Indiana University Hospital, Indianapolis, United States 11Albert Einstein College of Medicine, Montefiore Medical Center, New York, United States 12New York University School of Medicine, New York, United States

DOP023

Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium

Year: 2017
Source:

1University of California - San Diego, La Jolla, United States 2Indiana University School of Medicine, Indianapolis, United States 3Mayo Clinic, Rochester, United States 4Dartmouth-Hitchcock Medical Center, Lebanon, United States 5Cleveland Clinic Foundation, Cleveland, United States 6Icahn School of Medicine at Mount Sinai, New York, United States 7Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States 8North Shore University Hospital, Manhasset, United States 9Lenox Hill Hospital, New York, United States 10Indiana University Hospital, Indianapolis, United States 11Albert Einstein College of Medicine, Montefiore Medical Center, New York, United States 12New York University School of Medicine, New York, United States

Authors:

Dulai P.*1, Meserve J.1, Hartke J.2, Chilukuri P.2, Chaudrey K.3, Koliani-Pace J.L.4, Kochhar G.5, Parikh M.P.5, Shmidt E.6, Hirten R.6, Luo M.7, Barocas M.7, Lasch K.7, Sultan K.8, Swaminath A.9, Bohm M.10, Lukin D.11, Hudesman D.12, Shen B.5, Siegel C.A.4, Sands B.E.6, Colombel J.-F.6, Kane S.3, Loftus Jr. E.V.3, Singh S.1, Sandborn W.J.1, Boland B.S.1

DOP023

Safety and efficacy of a novel IV targeted pegylated liposomal prednisolone product (Nanocort): results from a phase 2a study in patients with active ulcerative colitis

Year: 2016
Authors:

G. van Assche1, P. Rutgeerts1, M. Ferrante1, M. Noman1, H. Fidder2, B. Oldenburg2, J. Metselaar3, 4, S. Vermeire*1

1University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, 2University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, 3Enceladus Pharmaceuticals, Naarden, Netherlands, 4University Clinic RWTH, Experimental Molecular Imaging, Aachen, Germany

Ulcerative Colitis (UC) is a chronic, relapsing inflammatory disease affecting the mucosal lining of the rectum and the colon to a variable extent. Corticosteroids have long been a cornerstone in the treatment of UC, despite considerable side effects including Cushingoid facies and weight gain, acne, hyperglycaemia, insomnia, infections, and osteoporosis after extended use. Nanocort is a novel pharmaceutical composed of prednisolone sodium phosphate enclosed in 100 nm PEGylated liposomes, which, after IV infusion, selectively target and accumulate in inflamed bowel lesions and selectively deliver high and effective concentrations of corticosteroids, thus reducing the required total steroid dose and dosing frequency.

In an exploratory, 2-centre (neoplastic lesions [NL] and BE), randomised, placebo-controlled, observer-blind phase 2a study, the safety and efficacy of Nanocort was evaluated in 18 patients aged 22–63 with moderate-to-severe active UC. Two IV doses of 150 mg Nanocort (n = 14) or saline (n = 4) were given as slow infusions 2 weeks apart. Overall safety (primary endpoint), pharmacokinetics, and efficacy were assessed at weeks 2, 4, 8, and 12 after start of treatment.

The median total Mayo score (tMS, 0–12) at baseline was 10 (range 7–12). At week 4 the Nanocort group showed clear benefit in 70% of the patients with 4 patients out of 13 in remission. Further, 7 out of 13 patients showed a reduction of the endoscopy sub score of ≥ 1 point reaching ≤ 1 point. Rapid effects on partial Mayo score (pMS, 0–9) were shown with persisting remissions in 7/13 patients treated with Nanocort. Remission was defined as a post-treatment MS of ≤ 2 points with all sub scores ≤ 1 point. Typical steroid-related adverse effects were sparse with isolated mild to moderate cases of acne, dyspepsia, nausea, and gastritis. No significant suppression of urinary cortisol was found, nor were there any indications of hyperglycaemia. Some patients experienced infusion reactions probably related to the trial medication. One patient experienced an exacerbation of psoriasis upon withdrawal.

The results of this phase 2a study demonstrate that IV Nanocort can be a safe new therapy with fast and durable therapeutic benefit for patients with active UC without the drawbacks of oral steroid standard-of-care. Larger studies are warranted.

Figure 1. Nanocort effect.

DOP024

Electrical vagus nerve stimulation as an innovative treatment in inflammatory bowel diseases

Year: 2016
Authors:

V. Sinniger1, 2, 3, S. Pellissier3, 4, D. Hoffmann5, C. Trocmé6, L. Vercueil3, 7, 
D. Clarençon3, 8, B. Bonaz*3, 9

1Hospital University Centre, Hepatogastroenterology, Grenoble Cx9, France, 2Hospital University Centre, Gastroenterology, Grenoble Cx9, France, 3Inserm U836, Grenoble, France, 4University of savoie Mont Blanc, Psychology department, chambéry, France, 5Hospital University Centre, Neurosurgery, Grenoble, France, 6Hospital University Centre, Biology, Grenoble, France, 7Hospital University Centre, Neurology, Grenoble Cx9, France, 8Research Institute of the French Army, Brétigny-sur-Orge, France, 9Hospital University Centre, Gastroenterology, Grenoble, France

DOP025

Clinical response to anti-MMP9 antibody (GS-5745) is accompanied by histologic improvement in ulcerative colitis

Year: 2016
Authors:

W. Sandborn1, 2, B. Bhandari3, R. Fogel4, J. Onken5, E. Yen6, E. Huntzicker6, Y. Xin6, D. French6, J. Silverman6, B. Kanwar6, M. Subramanian6, J. McHutchison6, S. Lee7, L. Shackelton8, L. Stitt8, R. Pai9, B. Levesque*2, G. D’Haens10, 11, B. Feagan8, 12

1University of California, San Diego, California, United States, 2Robarts Clinical Trials, San Diego, California, United States, 3Delta Research Partners, Monroe, Louisiana, United States, 4Clinical Research Institute of Michigan, LLC, Chesterfield, Michigan, United States, 5Duke University Medical Centre, Durham, North Carolina, United States, 6Gilead Sciences, Inc, Foster City, California, United States, 7University of Washington, Seattle, Washington, United States, 8Robarts Clinical Trials, London, Ontario, Canada, 9Mayo Clinic Arizona, Scottsdale, Arizona, United States, 10Academic Medical Centre, Amsterdam, Canada, 11Robarts Clinical Trials, Amsterdam, Netherlands, 12University of Western Ontario, London, Ontario, Canada

1University hospital Jena, Department of Internal Medicine IV, Jena, Germany 2Gastroenterology Practice, Private practice, Minden, Germany 3TDDA (Toronto Digestive Disease Associates Inc.), Toronto, Canada 4Takeda Development Centre Europe Ltd, Global Medical Affairs, London, United Kingdom 5Praxis für Gastroenterologie, Gastroenterology, Heidelberg, Germany 6Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials, London, Canada 7Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland 8Takeda Development Centre Europe Ltd, Global Statistics and Statistical Programming, London, United Kingdom 9Takeda Development Centre Europe Ltd, Clinical Development, London, United Kingdom 10Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom 11Atlanta Gastroenterology Associates, Emory Saint Joseph's, Atlanta, United States 12University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany

DOP026

Sustained remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis of week 14 remitters

Year: 2017
Source:

1University hospital Jena, Department of Internal Medicine IV, Jena, Germany 2Gastroenterology Practice, Private practice, Minden, Germany 3TDDA (Toronto Digestive Disease Associates Inc.), Toronto, Canada 4Takeda Development Centre Europe Ltd, Global Medical Affairs, London, United Kingdom 5Praxis für Gastroenterologie, Gastroenterology, Heidelberg, Germany 6Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials, London, Canada 7Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland 8Takeda Development Centre Europe Ltd, Global Statistics and Statistical Programming, London, United Kingdom 9Takeda Development Centre Europe Ltd, Clinical Development, London, United Kingdom 10Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom 11Atlanta Gastroenterology Associates, Emory Saint Joseph's, Atlanta, United States 12University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany

Authors:

Stallmach A.*1, Bokemeyer B.2, Axler J.3, Curtis R.4, Ehehalt R.5, Feagan B.6, Geransar P.7, James A.8, Kaviya A.9, Khalid J.M.10, Wolf D.11, Schreiber S.12

DOP026

The Toll-like-receptor 9 agonist DIMS0150 demonstrates therapeutic efficacy for the patient-reported outcome measures PRO-2 and ClinPRO in moderate-to-severe active ulcerative colitis

Year: 2016
Authors:

R. Atreya*1, S. Bloom2, F. Scaldaferi3, V. Gerardi4, C. Admyre5, A. Karlsson5, T. Knittel5, J. Kowalski5, M. Lukas6, R. Löfberg7, R. Petryka8, R. Schnabel9, U. Seidler10, S. Nancey11, M. Neurath1, C. Hawkey12

1University of Erlangen-Nuernberg, Department of Medicine 1, Erlangen, Germany, 2University College London Hospital, Department of Gastroenterology, London, United Kingdom, 3Catholic University of Rome, Internal Medicine Department / Gastroenterology Division, Rome, Italy, 4Catholic University of Rome, Rome, Italy, 5Index Pharmaceuticals, Stockholm, Sweden, 6IBD Clinical and Research Centre, Clinical Centre Isacre Lighthouse, Prague, Czech Republic, 7Karolinska Institute and Sophiahemmet, Stockholm, Sweden, 88NZOZ Vivamed, Warsaw, Poland, 9Pannonia Maganorvosi Centrum, Budapest, Hungary, 10MHH, Department of Gastroenterology, Hepatology, and Endocrinology, Hannover, Germany, 11Lyon-Sud Hospital, Department of Gastroenterology, Lyon, France, 12Nottingham University Hospitals, Department of Gastroenterology, Nottingham, United Kingdom

DOP027

Large-scale drug screen reveals benzimidazole anti-helminthics as potential anti-TNF co-therapy

Year: 2016
Authors:

M. Wildenberg*1, A. Levin2, A. Ceroni3, Z. Guo2, F. Bloemendaal2, D. Ebner3, G. van den Brink1

1Academic Medical Centre, Gastroenterology and Hepatology, Amsterdam, Netherlands, 2Academic Medical Centre, Tytgat Institute, Amsterdam, Netherlands, 3Oxford University, Target Discovery Institute, Oxford, United Kingdom

1University of Lille 2, Department of Gastroenterology, Lille, France 2Beaujon Hospital, Gastroenterology Unit, Clichy, France 3University Hospital Lausanne, Division of Gastroenterology & Hepatology, Lausanne, Switzerland 4Centre Hospitalier Lyon-Sud, Service d'Hépato-gastro-entérologie, Lyon, France 5CHU de Reims, Gastroenterologie, Reims, France 6University Hospital of Saint Antoine, APHP, Gastroenterology, Paris, France 7APHP, Hopital Saint Louis, Department of Gastroenterology, Paris, France 8Université de Strasbourg, Gastroenterology, Strasbourg, France 9Hospital Nord Assistance Publique de Marseille, Department of Gastroenterology, Marseille, France 10Clermont-Ferrand University, Clermont-Ferrand, France 11Hospital Henri-Mondor, Department of Gastroenterology, Creteil, France 12Amiens University Hospital, Gastroenterology, Amiens, France 13University of Saint Etienne, Department of Gastroenterology, Saint Etienne, France 14CHU Nancy, Department of Gastroenterology, Nancy, France 15CHU de Nice, Department of Gastroenterology, Nice, France 16CHU Rennes, Department of HepatoBiliary Surgery and Digestive, Rennes, France 17Cochin University Hospital, Gastroenterology, Paris, France 18Hopital Louis-Mourier, Gastroenterologie, Colombes, France 19Institut Mutualiste Montsouris, Gastroenterology, Paris, France 20CHU de Bordeaux, Gastroenterology, Pessac, France

DOP027

Long-term efficacy and safety of ustekinumab in refractory Crohn's disease patients: a multicenter retrospective experience

Year: 2017
Source:

1University of Lille 2, Department of Gastroenterology, Lille, France 2Beaujon Hospital, Gastroenterology Unit, Clichy, France 3University Hospital Lausanne, Division of Gastroenterology & Hepatology, Lausanne, Switzerland 4Centre Hospitalier Lyon-Sud, Service d'Hépato-gastro-entérologie, Lyon, France 5CHU de Reims, Gastroenterologie, Reims, France 6University Hospital of Saint Antoine, APHP, Gastroenterology, Paris, France 7APHP, Hopital Saint Louis, Department of Gastroenterology, Paris, France 8Université de Strasbourg, Gastroenterology, Strasbourg, France 9Hospital Nord Assistance Publique de Marseille, Department of Gastroenterology, Marseille, France 10Clermont-Ferrand University, Clermont-Ferrand, France 11Hospital Henri-Mondor, Department of Gastroenterology, Creteil, France 12Amiens University Hospital, Gastroenterology, Amiens, France 13University of Saint Etienne, Department of Gastroenterology, Saint Etienne, France 14CHU Nancy, Department of Gastroenterology, Nancy, France 15CHU de Nice, Department of Gastroenterology, Nice, France 16CHU Rennes, Department of HepatoBiliary Surgery and Digestive, Rennes, France 17Cochin University Hospital, Gastroenterology, Paris, France 18Hopital Louis-Mourier, Gastroenterologie, Colombes, France 19Institut Mutualiste Montsouris, Gastroenterology, Paris, France 20CHU de Bordeaux, Gastroenterology, Pessac, France

Authors:

Wils P.*1, Bouhnik Y.2, Michetti P.3, Flourie B.4, Brixi H.5, Bourrier A.6, Allez M.7, Duclos B.8, Serrero M.9, Buisson A.10, Amiot A.11, Fumery M.12, Roblin X.13, Peyrin-Biroulet L.14, Filippi J.15, Bouguen G.16, Abitbol V.17, Coffin B.18, Simon M.19, Laharie D.20, Pariente B.1

1KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium 2University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium

DOP028

Antibodies towards vedolizumab appear from week 2 onwards and disappear upon treatment

Year: 2017
Source:

1KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium 2University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium

Authors:

Bian S.*1, Tang H.T.1, Peeters M.1, Compernolle G.1, Dreesen E.1, Van Assche G.2, Ferrante M.2, Vermeire S.2, Gils A.1

DOP028

Efficacy and safety of biosimilar infliximab after one year: results from a prospective nationwide cohort

Year: 2016
Authors:

K. Gecse*1, Z. Vegh1, Z. Kurti1, M. Rutka2, K. Farkas2, J. Banai3, L. Bene4, B. Gasztonyi5, P. A. Golovics1, T. Kristof6, L. Lakatos7, P. Miheller8, F. Nagy9, K. Palatka10, M. Papp11, L. Lakner12, A. Patai13, A. Salamon14, T. Szamosi3, Z. Szepes9, B. Szalay15, G. T. Toth16, A. Vincze17, T. Molnar2, P. Lakatos1

1Semmelweis University, First Department of Medicine, Budapest, Hungary, 2University of Szeged, First Department of Medicine, Szeged, Hungary, 3Military Hospital, State Health Centre, Department of Gastroenterology, Budapest, Hungary, 4Peterfy Hospital, First Department of Medicine, Budapest, Hungary, 5Zala County Hospital, Second Department of Medicine, Zalaegerszeg, Hungary, 6B-A-Z County and University Teaching Hospital, Second Department of Medicine, Miskolc, Hungary, 7Csolnoky F. Province Hospital, Department of Medicine, Veszprem, Hungary, 8Semmelweis University, Second Department of Medicine, Budapest, Hungary, 9University of Szeged, First Department of Internal Medicine, Szeged, Hungary, 10University of Debrecen, Institute of Medicine, Department of Gastroenterology, Debrecen, Hungary, 11University of Debrecen, Institute of Internal Medicine, Department of Gastroenterology, Debrecen, Hungary, 12Markusovszky Hospital, Department of Medicine and Gastroenterology, Szombathely, Hungary, 13Markusovszky Hospital, First Department of Medicine and Gastroenterology, Szombathely, Iceland, 14Tolna County Teaching Hospital, First Department of Gastroenterology, Szekszard, Hungary, 15Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary, 16Janos Hospital, Department of Gastroenterology, Budapest, Hungary, 17University of Pécs, First Department of Medicine, Pécs, Hungary

1KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium 2UZ Leuven, Department of Clinical and Experimental Medicine, Leuven, Belgium

DOP029

Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post-hoc analysis of the taxit trial

Year: 2017
Source:

1KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium 2UZ Leuven, Department of Clinical and Experimental Medicine, Leuven, Belgium

Authors:

Van Stappen T.*1, Vande Casteele N.1, Van Assche G.2, Ferrante M.2, Vermeire S.2, Gils A.1

DOP029

Outcomes of a managed switching programme changing IBD patients established on originator infliximab to biosimilar infliximab

Year: 2016
Authors:

M. Bettey1, L. Downey1, C. Underhill1, J. Callaghan1, M. Rush2, I. Ahmed1, F. Cummings*1

1University Hospital Southampton NHS Trust, Department of Gastroenterology, Southampton, United Kingdom, 2University of Southampton, Department of Gastroenterology, Southampton, United Kingdom

1Eastern Health, Gastroenterolgy, Melbourne, Australia 2Monash University, Melbourne, Australia 3Alfred Health, Gastroenterology, Melbourne, Australia

DOP030

Anti-TNF re-induction is as effective, simpler and cheaper compared with dose interval shortening following secondary loss of response in Crohn's disease: a dual centre “real world” study

Year: 2017
Source:

1Eastern Health, Gastroenterolgy, Melbourne, Australia 2Monash University, Melbourne, Australia 3Alfred Health, Gastroenterology, Melbourne, Australia

Authors:

Srinivasan A.*1, Vasudevan A.1,2,3, McFarlane A.1, Gibson P.2,3, Sparrow M.2,3, van Langenberg D.1,2

DOP030

Elective switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study

Year: 2016
Authors:

L. Smits*, L. Derikx, J. Drenth, D. de Jong, A. van Esch, F. Hoentjen

Radboud University Medical Centre, Inflammatory Bowel Disease Centre, Department of Gastroenterology and Hepatology, Nijmegen, Netherlands

DOP031

Efficacy of infliximab biosimilar CT-P13 therapy on mucosal healing in ulcerative colitis: data from 2 Central European countries

Year: 2016
Authors:

K. Farkas1, M. Rutka1, P.A. Golovics2, Z. Végh2, B.D. Lovász2, T. Nyári3, K.B. Gecse2, M. Kolar4, 5, M. Bortlik4, 6, D. Duricova4, 7, N. Machkova4, V. Hruba4, M. Lukas4, K. Mitrova4, 8, K. Malickova9, A. Bálint1, F. Nagy1, R. Bor*1, A. Milassin1, Z. Szepes1, K. Palatka10, P.L. Lakatos2, M. Lukas4, 9, T. Molnár1

1University of Szeged, First Department of Medicine, Szeged, Hungary, 2Semmelweis University, First Department of Medicine, Budapest, Hungary, 3University of Szeged, Department of Medical Physics and Informatics, Szeged, Hungary, 4IBD Clinical and Research Centre, Iscare a.s, Prague, Czech Republic, 5Charles University, First Medical Faculty, Prague, Czech Republic, 6Military Hospital, Charles University, Department of Internal Medicine, Prague, Czech Republic, 7 First Medical Faculty, Charles University, Institute of Pharmacology, Prague, Czech Republic, 8Faculty Hospital Motol, 2nd Medical Faculty, Charles University, Department of Paediatrics, Prague, Czech Republic, 9 First Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic, 10University of Debrecen, Second Department of Medicine, Debrecen, Hungary

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 146 ()